Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets
MedComm · 2025-12 · 6 (12)
DOI: 10.1002/mco2.70545 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 14.12.2025. Verfasst von Zhi-Min Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics Shanghai Eighth People's Hospital Shanghai China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 365 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Alternative splicing (AS) is an important posttranscriptional process that increases proteomic complexity of eukaryotes. Through the selective inclusion or exclusion of exons, AS fine‐tunes gene expression and underpins diverse biological processes. Recent research revealed that AS is controlled not only by spliceosomal components but also by dynamic RNA structures and the spatial compartmentalization of splicing factors within biomolecular condensates formed via liquid–liquid phase separation (LLPS). Nevertheless, a unified framework connecting these mechanistic insights with emerging therapeutic strategies remains lacking. This review systematically integrates current knowledge of AS regulation, encompassing the architecture and dynamics of the core spliceosome, structural RNA elements such as G‐quadruplexes, and LLPS‐driven condensates exemplified by oncogenic SRSF9 droplets. It further delineates how AS influences cell development, immune modulation, and stress adaptation, while its dysregulation contributes to human pathologies, including SF3B1 mutant cancers, TDP‐43‐associated neurodegeneration, and cardiovascular disease. We critically appraise therapeutic innovations targeting aberrant splicing, including small molecule spliceosome modulators, antisense oligonucleotides like nusinersen, and CRISPR/dCas13‐based RNA editing. By integrating molecular mechanisms with translational advances, this review provides a conceptual framework to accelerate RNA‐targeted precision medicine in the era of spatial multiomics and artificial intelligence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutics Shanghai Eighth People's Hospital Shanghai China.
- Department of Pharmacy Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China.
- Clinical Laboratory Center The First Hospital of Hunan University of Chinese Medicine Changsha Hunan China.
- Department of Pharmacy RuiJin Hospital Lu Wan Branch Shanghai Jiao Tong University School of Medicine Shanghai China.
- Department of Pharmacy Henan Provincial People's Hospital People's Hospital of Zhengzhou University School of Clinical Medicine Henan University Zhengzhou Henan China.
Zitieren
APA
Zhu, Z. M., Wu, X. M., Hu, Y., Bian, X. L., Wang, Y. Q., & Zhu, Q. N. (2025). Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets. MedComm, 6(12). https://doi.org/10.1002/mco2.70545
Vancouver
Zhu ZM, Wu XM, Hu Y, Bian XL, Wang YQ, Zhu QN. Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets. MedComm. 2025;6(12). doi:10.1002/mco2.70545
BibTeX
@article{Zhu2025,
author = {Zhu, Zhi-Min and Wu, Xiao-Mei and Hu, Yan and Bian, Xiao-Lan and Wang, Ya-Qin and Zhu, Qiong-Ni},
title = {Alternative Splicing: Molecular Mechanisms, Biological Functions, Diseases, and Potential Therapeutic Targets},
journal = {MedComm},
year = {2025},
volume = {6},
number = {12},
doi = {10.1002/mco2.70545}
}
EUVIMED